Details of the Drug
General Information of Drug (ID: DMJPBAX)
Drug Name |
Oxybutynine
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
5633-20-5; Ditropan; Oxytrol; Oxibutyninum; Oxybutyninum; Oxibutinina; Oxybutyninum [INN-Latin]; Oxybutynine [INN-French]; Oxybutinin; Cystrin; Oxibutinina [INN-Spanish]; Oxybutynin Base; transdermal patch; Lyrinel XL; Oxybutynin [USAN:INN:BAN]; 4-Diethylamino-2-butinyl alpha-cyclohexylmandelat; CCRIS 1923; oxybutynin topical gel; Ditropan Xl; Oxybutynin (Ditropan); HSDB 3270; 4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate; CHEMBL1231; Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-b
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 357.5 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 4.2 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 8 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 4 | |||||||||||||||||||
ADMET Property |
|
|||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
Drug-Drug Interaction (DDI) Information of This Drug
Coadministration of a Drug Treating the Disease Different from Oxybutynine (Comorbidity)
|
Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug
References
1 | Generation of an agonistic binding site for blockers of the M(3) muscarinic acetylcholine receptor. Biochem J. 2008 May 15;412(1):103-12. | ||||
---|---|---|---|---|---|
2 | FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41. | ||||
3 | BDDCS applied to over 900 drugs | ||||
4 | Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds | ||||
5 | Douchamps J, Derenne F, Stockis A, Gangji D, Juvent M, Herchuelz A: The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol. 1988;35(5):515-20. doi: 10.1007/bf00558247. | ||||
6 | A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol. 2010 Winter;12(1):12-9. | ||||
7 | Legrand E: Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57. | ||||
8 | Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose | ||||
9 | Ditropan XL FDA label | ||||
10 | Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther. 2004 Jun;309(3):1148-53. | ||||
11 | Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4- oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists. J Med Chem. 1993 Apr 2;36(7):842-7. | ||||
12 | DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6. | ||||
13 | Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.Chem Immunol Allergy.2012;98:48-69. | ||||
14 | M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor. Pharmacol Res. 2009 May;59(5):300-5. | ||||
15 | Muscarinic M3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am J Respir Cell Mol Biol. 2003 Feb;28(2):257-62. | ||||
16 | Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):2059-64. | ||||
17 | Comparison of muscarinic receptor selectivity of solifenacin and oxybutynin in the bladder and submandibular gland of muscarinic receptor knockout ... Eur J Pharmacol. 2009 Aug 1;615(1-3):201-6. | ||||
18 | Interaction of neuromuscular blocking drugs with recombinant human m1-m5 muscarinic receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1998 Nov;125(5):1088-94. | ||||
19 | Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor ... Am J Physiol Gastrointest Liver Physiol. 2008 Jul;295(1):G112-G123. | ||||
20 | Cerner Multum, Inc. "UK Summary of Product Characteristics.". | ||||
21 | Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA. | ||||
22 | Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232] | ||||
23 | Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469] | ||||
24 | Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA. | ||||
25 | Multum Information Services, Inc. Expert Review Panel. | ||||
26 | Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031] | ||||
27 | Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA. | ||||
28 | Product Information. GenESA (arbutamine). Gensia Inc, San Diego, CA. | ||||
29 | Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ. | ||||
30 | Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ. | ||||
31 | EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.". | ||||
32 | Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA. | ||||
33 | Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469] | ||||
34 | Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ. | ||||
35 | Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA. | ||||
36 | Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO. | ||||
37 | Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ. | ||||
38 | Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ. | ||||
39 | Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC. | ||||
40 | Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA. | ||||
41 | Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY. | ||||
42 | Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA. | ||||
43 | Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA. | ||||
44 | Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
45 | Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA. | ||||
46 | Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ. | ||||
47 | Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ. | ||||
48 | Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON. | ||||
49 | Beermann B, Groschinsky-Grind M "Enhancement of the gastrointestinal absorption of hydrochlorothiazide by propantheline." Eur J Clin Pharmacol 13 (1978): 385-7. [PMID: 668798] | ||||
50 | EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.". | ||||
51 | Algeri S, Cerletti C, Curcio M, et al. "Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and man." Eur J Pharmacol 35 (1976): 293-9. [PMID: 1248506] | ||||
52 | Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ. | ||||
53 | Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA. | ||||
54 | Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA. | ||||
55 | Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501] | ||||
56 | Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA. | ||||
57 | Cerner Multum, Inc. "Australian Product Information.". | ||||
58 | Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143] | ||||
59 | DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902] | ||||
60 | Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA. | ||||
61 | Product Information. Symlin (pramlintide). Amphastar Pharmaceuticals Inc, South El Monte, CA. | ||||